DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Definium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$32.97+0.87 (+2.71%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$19.32 (+141.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.65B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.97
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$353.79M
- EPS, diluted
- -$3.43
- Book value per share
- $8.30
- Diluted shares
- 111M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$227.54M
Net income
-$353.79M
EPS, diluted
-$3.43
Reported periodTrailing twelve months